- Home
- COE vs ELOX Comparison
COE vs ELOX Comparison
Compare COE & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COE | ELOX |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.1M | 60.3M |
| IPO Year | 2015 | 2013 |
Fundamental Metrics
Financial Performance| Metric | COE | ELOX |
|---|---|---|
| Price | $11.46 | $13.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $38.25 |
| AVG Volume (30 Days) | ★ 26.0K | 17.7K |
| Earning Date | 12-07-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $70.66 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.93 | $10.00 |
| 52 Week High | $52.00 | $23.40 |
Technical Indicators
Market Signals| Indicator | COE | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 40.05 |
| Support Level | $9.95 | $10.74 |
| Resistance Level | $12.48 | $14.65 |
| Average True Range (ATR) | 0.84 | 1.28 |
| MACD | 0.22 | -0.04 |
| Stochastic Oscillator | 68.34 | 21.89 |
Price Performance
Historical ComparisonAbout COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in geographical areas: Asia-Pacific region; and Other areas, of which it derives maximum revenue from Asia-Pacific.
About ELOX Eloxx Pharmaceuticals Inc. Common Stock
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.